|
Like a Zen master of the drugmaking world, Vasogen strives to have a calming influence, at least on inflammatory responses associated with cardiovascular and neurological disease. The company is focused on a set of early-stage compounds that may treat some neurological diseases (such as Parkinson's disease) by targeting inflammation. Its lead candidate had been the Celacade system, a technology that treats chronic heart failure using patients' own blood; however, in 2008 the company put Celacade development on hold following a setback with the FDA. Vasogen then restructured and slashed its workforce, and in mid-2009 it announced plans to merge with private drug developer IntelliPharmaCeutics.
|
| | | Contact Information | |
Address: |
4 Robert Speck Parkway, 15th Fl.
Mississauga, Ontario L4Z 1S1, Canada
| | Phone: | 905-402-9925 | | Fax: | 905-847-6270 |
|
| Financial
Highlights | | Fiscal Year End: | November | | Revenue (2008): | 0.00 M | | Employees (2008): | 6 |
|
|
Key People
| | • |
Chairman:
Eldon R. Smith
| | • |
VP Finance and CFO:
Graham D. Neil
| | • |
Director, Investor and Public Relations:
Glenn Neumann
|
|
|
